Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...

Lonza acquired Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of more effective and better tolerated antibody-drug conjugates ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Prague headquartered clinical-stage firm SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it ...

North Boulder Dental is thrilled to announce the launch of its newly designed website, which is now live at The revamped site offers an improved user experience, making it easier for patients to ...

Mike Valli as Chief Commercial Officer (CCO) and Scott Sbihli as Chief Product Officer (CPO). These appointments contribute ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

Three-program alliance with Synaffix reflects SOTIO's commitment to further broaden and advance innovative ADC pipeline SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF ...

公司还提名EO-1022作为针对HER3表达实体瘤的开发候选药物，预计将在2026年提交研究性新药申请。 Elevation Oncology最近宣布与Synaffix B.V.达成全球许可协议，获得使用Synaffix的ADC技术平台的权限。该协议旨在促进EO-1022的开发，利用创新技术进行靶向癌症治疗。在领导 ...